BUZZ-<a href="https://laohu8.com/S/SMMT">Summit</a> rises after FDA accepts marketing application for lung cancer drug** Shares of drug developer Summit Therapeutics SMMT.O rise 3.71% to $16.22 premarket
** Co says the U.S. Food and Drug Administration has accepted its application to market its experimental drug to treat lung cancer
** Reports mixed results from patient subgroups in a longer-term follow-up of its late-stage trial in September
** The therapy is an antibody designed to block a protein called PD-1, which helps the body's immune system fend off cancer; Keytruda also targets the same protein
** The health regulator has assigned a new Prescription Drug User Fee Act (PDUFA) target action date for November 14, 2026 - SMMT
** Stock fell ~2% in 2025
(Reporting by Gnaneshwar Rajan in Bengaluru)
((Gnaneshwar.Rajan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments